Arcutis Biotherapeutics, Inc. ARQT revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Arcutis Biotherapeutics, Inc. reported revenue across 1 business segments; the largest, Reportable Segment, was $376M, 100.0% of the filed sum (+91.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$376M100.0%+91.3% yoy
Members sum to the consolidated $372M for this period.
- Reportable Segment-$12.2M100.0%-90.5% yoy
Members sum to the consolidated -$12.2M for this period.
- ZORYVE Foam$182M48.9%+154.3% yoy
- ZORYVE Cream0.3$121M32.5%+42.2% yoy
- ZORYVE Cream0.15$68.3M18.3%+588.2% yoy
- ZORYVE Cream0.05$911K0.2%no prior
Members sum to the consolidated $372M for this period.
- Reportable Segment$105M100.0%+60.1% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.